KIT and neoplasm: Anlotinib was developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. as a new oral molecular RTK inhibitor; it targets VEGFR1, VEGFR3, VEGFR2/KDR, PDGFR-α, c-Kit, and FGFRs 1–3 and inhibits TA and tumor cell proliferation (31, 41–43).